Logo image of DBV.PA

DBV TECHNOLOGIES SA (DBV.PA) Stock Fundamental Analysis

EPA:DBV - Euronext Paris - Matif - FR0010417345 - Common Stock - Currency: EUR

1.852  -0.06 (-2.94%)

Fundamental Rating

2

Overall DBV gets a fundamental rating of 2 out of 10. We evaluated DBV against 68 industry peers in the Biotechnology industry. DBV may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, DBV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DBV has reported negative net income.
DBV had a negative operating cash flow in the past year.
In the past 5 years DBV always reported negative net income.
In the past 5 years DBV always reported negative operating cash flow.
DBV.PA Yearly Net Income VS EBIT VS OCF VS FCFDBV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -174.12%, DBV is not doing good in the industry: 83.58% of the companies in the same industry are doing better.
DBV has a Return On Equity of -416.74%. This is in the lower half of the industry: DBV underperforms 68.66% of its industry peers.
Industry RankSector Rank
ROA -174.12%
ROE -416.74%
ROIC N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
DBV.PA Yearly ROA, ROE, ROICDBV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

Looking at the Gross Margin, with a value of 83.62%, DBV is in the better half of the industry, outperforming 77.61% of the companies in the same industry.
DBV's Gross Margin has declined in the last couple of years.
DBV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
DBV.PA Yearly Profit, Operating, Gross MarginsDBV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

2

2. Health

2.1 Basic Checks

DBV does not have a ROIC to compare to the WACC, probably because it is not profitable.
DBV has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, DBV has more shares outstanding
Compared to 1 year ago, DBV has a worse debt to assets ratio.
DBV.PA Yearly Shares OutstandingDBV.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DBV.PA Yearly Total Debt VS Total AssetsDBV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

DBV has an Altman-Z score of -7.04. This is a bad value and indicates that DBV is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.04, DBV is doing worse than 73.13% of the companies in the same industry.
A Debt/Equity ratio of 0.23 indicates that DBV is not too dependend on debt financing.
DBV has a Debt to Equity ratio of 0.23. This is comparable to the rest of the industry: DBV outperforms 56.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z -7.04
ROIC/WACCN/A
WACC7.44%
DBV.PA Yearly LT Debt VS Equity VS FCFDBV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

DBV has a Current Ratio of 1.43. This is a normal value and indicates that DBV is financially healthy and should not expect problems in meeting its short term obligations.
DBV's Current ratio of 1.43 is on the low side compared to the rest of the industry. DBV is outperformed by 67.16% of its industry peers.
A Quick Ratio of 1.43 indicates that DBV should not have too much problems paying its short term obligations.
DBV's Quick ratio of 1.43 is on the low side compared to the rest of the industry. DBV is outperformed by 62.69% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.43
DBV.PA Yearly Current Assets VS Current LiabilitesDBV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for DBV have decreased strongly by -53.92% in the last year.
The Revenue for DBV has decreased by -73.61% in the past year. This is quite bad
Measured over the past years, DBV shows a very negative growth in Revenue. The Revenue has been decreasing by -22.35% on average per year.
EPS 1Y (TTM)-53.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.92%
Revenue 1Y (TTM)-73.61%
Revenue growth 3Y-10.07%
Revenue growth 5Y-22.35%
Sales Q2Q%-85.92%

3.2 Future

DBV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.98% yearly.
Based on estimates for the next years, DBV will show a very strong growth in Revenue. The Revenue will grow by 142.59% on average per year.
EPS Next Y-5.31%
EPS Next 2Y42.2%
EPS Next 3Y21.98%
EPS Next 5YN/A
Revenue Next Year2860%
Revenue Next 2Y1271.71%
Revenue Next 3Y91.26%
Revenue Next 5Y142.59%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DBV.PA Yearly Revenue VS EstimatesDBV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
DBV.PA Yearly EPS VS EstimatesDBV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DBV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DBV.PA Price Earnings VS Forward Price EarningsDBV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DBV.PA Per share dataDBV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as DBV's earnings are expected to grow with 21.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.2%
EPS Next 3Y21.98%

More info and screens

0

5. Dividend

5.1 Amount

DBV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DBV TECHNOLOGIES SA

EPA:DBV (7/11/2025, 7:00:00 PM)

1.852

-0.06 (-2.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01
Earnings (Next)08-04 2025-08-04
Inst Owners48.3%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap50.65M
Analysts82.5
Price Target3.96 (113.82%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-37.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-50.66%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.25
P/FCF N/A
P/OCF N/A
P/B 2.16
P/tB 2.16
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-3.3
FCFYN/A
OCF(TTM)-3.23
OCFYN/A
SpS0.13
BVpS0.86
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -174.12%
ROE -416.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.62%
FCFM N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 317.64%
Cap/Sales 56.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 1.43
Altman-Z -7.04
F-Score1
WACC7.44%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.42%
Cap/Sales(5y)23.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.92%
EPS Next Y-5.31%
EPS Next 2Y42.2%
EPS Next 3Y21.98%
EPS Next 5YN/A
Revenue 1Y (TTM)-73.61%
Revenue growth 3Y-10.07%
Revenue growth 5Y-22.35%
Sales Q2Q%-85.92%
Revenue Next Year2860%
Revenue Next 2Y1271.71%
Revenue Next 3Y91.26%
Revenue Next 5Y142.59%
EBIT growth 1Y-52.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.53%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.89%
OCF growth 3YN/A
OCF growth 5YN/A